Larvol Veri

BIOMARKER:

RAD51D mutation

Entrez ID:

RAD51D mutation RAD51D mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
RAD51D mutation RAD51D mutation	Ovarian Cancer Ovarian Cancer	rucaparib Sensitive: B - Late Trials rucaparib Sensitive : B
RAD51D mutation RAD51D mutation	Small Cell Lung Cancer Small Cell Lung Cancer	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2
RAD51D mutation RAD51D mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and